Exicure, Inc.
XCUR · Nasdaq · United States
Share price · XCUR
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when XCUR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 10 Nov 2026+21.3%
- 22 Oct 2026+11.9%
Nothing announced by XCUR that day or the session before.
- 8 Sep 2026+12.8%
Nothing announced by XCUR that day or the session before.
- 20 Jul 2026+12.5%
Nothing announced by XCUR that day or the session before.
- 22 Jun 2026+18.6%
Nothing announced by XCUR that day or the session before.
- 16 Jun 2026-22.2%
Nothing announced by XCUR that day or the session before.
- 4 Jun 2026-6.3%
Nothing announced by XCUR that day or the session before.
- 18 May 2026+7.7%
Nothing announced by XCUR that day or the session before.
- 10 Dec 2025-27.0%
Nothing announced by XCUR that day or the session before.
Share of unusual movement by asset
For each asset, the share of XCUR's own-move activity since 14 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Burixafor (TG-0054)events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 12% |
| Other company news (earnings, financing, releases naming no asset) | — | 4% |
| Sessions with no dated event | — | 85% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | CXCR4Small molecule | Multiple Myeloma |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (14)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $0.2M | $1.7M | $1.1M-$0.9M operating cash flow | report ↗ |
View 13 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $0 | $0.3M | $2.6M | $1.8M-$1.1M operating cash flow | report ↗ |
| 2025-Q3 | — | $0.9M | $4.4M | $2.4M-$3.5M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $0.9M | $7.9M | $2.6M-$2.3M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $0.8M | $10M | —-$1.6M operating cash flow | report ↗ |
| 2024-Q3 | — | $0 | $0.9M | $1.1M-$0.5M operating cash flow | report ↗ |
| 2024-Q2 | — | $0 | $1.4M | $0.6M-$1.2M operating cash flow | report ↗ |
| 2024-Q1 | — | $0 | $1.6M | $0.8M-$0.5M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $0 | $2.1M | $5.3M-$1.4M operating cash flow | report ↗ |
| 2023-Q2 | $0 | $0.9M | $3.5M | $5.8M-$4.8M operating cash flow | report ↗ |
| 2023-Q1 | $0 | $2.0M | $11M | $4.4M-$3.3M operating cash flow | report ↗ |
| 2022-Q3 | $2.0M | $4.8M | $17M+ $0 short-term inv. | $5.2M-$6.5M operating cash flow | report ↗ |
| 2022-Q2 | $2.5M | $6.8M | $22M+ $1.0M short-term inv. | $7.5M-$9.1M operating cash flow | report ↗ |
| 2022-Q1 | $2.6M | $7.1M | $25M+ $2.5M short-term inv. | $8.3M-$13M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | $3.3M | $3.8M | $1.2M-$8.6M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0.5M | $0 | $13M | $2.4M-$2.9M operating cash flow | report ↗ |
| 2023-FY | $0 | $1.4M | $2.0M | $4.2M-$10M operating cash flow | report ↗ |
| 2022-FY | $29M | $20M | $9.8M+ $0 short-term inv. | $0.7M-$36M operating cash flow | report ↗ |
| 2021-FY | -$0.5M | $49M | $44M+ $4.5M short-term inv. | $16M-$35M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 4 sales ($11.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-07-08 | Exicure HiTron Inc. · 10% owner | Other (see filing) | 117,441 | $4.50 | $528K | Form 4 |
| 2026-06-26 | Exicure HiTron Inc. · 10% owner | Other (see filing) | 253,195 | $4.50 | $1.1M | Form 4 |
| 2026-06-24 | Exicure HiTron Inc. · 10% owner | Other (see filing) | 123,456 | $4.50 | $556K | Form 4 |
| 2026-06-23 | Exicure HiTron Inc. · 10% owner | Other (see filing) | 129,183 | $4.50 | $581K | Form 4 |
| 2026-02-16 | Miller Josh · Chief Accounting Officer | Tax withholding | 8 | $4.08 | $33 | Form 4 |
| 2026-01-21 | Exicure HiTron Inc. · 10% owner | Open-market sale | 258,367 | $4.50 | $1.2M | Form 4 |
| 2026-01-16 | Exicure HiTron Inc. · 10% owner | Open-market sale | 734,747 | $4.50 | $3.3M | Form 4 |
| 2026-01-07 | Exicure HiTron Inc. · 10% owner | Open-market sale | 741,272 | $4.50 | $3.3M | Form 4 |